Moderna (MRNA) Expected to Announce Earnings on Thursday

Moderna (NASDAQ:MRNA) is projected to announce its earnings results before the market opens on Thursday, February 27th. Analysts expect the company to announce earnings of ($2.93) per share and revenue of $977.11 million for the quarter. Investors that wish to register for the company’s conference call can do so using this link.

Moderna Stock Down 4.6 %

Shares of NASDAQ:MRNA opened at $33.90 on Tuesday. Moderna has a fifty-two week low of $29.25 and a fifty-two week high of $170.47. The firm has a 50-day simple moving average of $37.89 and a 200 day simple moving average of $52.10. The company has a market cap of $13.05 billion, a PE ratio of -3.65 and a beta of 1.59.

Insider Buying and Selling

In other news, insider Shannon Thyme Klinger sold 1,418 shares of the business’s stock in a transaction that occurred on Friday, November 29th. The shares were sold at an average price of $42.79, for a total transaction of $60,676.22. Following the sale, the insider now owns 19,717 shares in the company, valued at $843,690.43. The trade was a 6.71 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have sold 2,664 shares of company stock worth $115,210 in the last ninety days. 15.20% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on MRNA shares. The Goldman Sachs Group downgraded shares of Moderna from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $99.00 to $51.00 in a research report on Wednesday, January 29th. Argus lowered shares of Moderna from a “buy” rating to a “hold” rating in a research note on Wednesday, December 18th. Morgan Stanley reduced their target price on shares of Moderna from $70.00 to $38.00 and set an “equal weight” rating for the company in a research note on Wednesday, January 15th. Hsbc Global Res raised shares of Moderna from a “hold” rating to a “strong-buy” rating in a research note on Monday, November 18th. Finally, UBS Group reduced their price target on shares of Moderna from $96.00 to $78.00 and set a “buy” rating for the company in a research note on Wednesday, February 19th. Four investment analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $60.63.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.